Depo-Provera Lawsuit Settlement Amounts

Research Linking Depo-Provera to Meningioma (Brain Tumors)

The research linking Depo-Provera to Meningioma was a large national case-control analysis conducted using the French National Health Data System, which includes over 108,000 women.

It focused on analyzing 18,061 women who underwent intracranial meningioma surgery from 2009 to 2018, matched with 90,305 control participants based on age and residence.

This national case-control analysis assessed the potential risk of developing intracranial meningiomas associated with various progestogens, such as the active ingredient in Depo-Provera.

Through this design, researchers examined exposure duration and dosage to evaluate if long-term use of specific progestogens influenced the likelihood of requiring surgical intervention for meningiomas.

Grade I Meningiomas (Non-Cancerous)

Grade I meningiomas are the most common form of brain tumors associated with progestogen use, accounting for the majority of benign, slow-growing meningiomas found in this study.

Although non-cancerous, these tumors can press against nearby brain structures, causing neurological symptoms that often necessitate surgery.

The study identified a higher incidence of Grade I meningiomas in women with prolonged exposure to medroxyprogesterone acetate, especially those using it as a contraceptive.

These findings underscore the need for monitoring patients who are long-term users of such progestogens, as even benign tumors can significantly impact health due to their location and size.

Grade II Meningiomas (Non-Cancerous but Atypical)

Grade II meningiomas, though also non-cancerous, are atypical and have a higher recurrence rate after treatment compared to Grade I.

This study observed that prolonged exposure to medroxyprogesterone acetate correlated with an increased likelihood of developing these atypical meningiomas.

Due to their propensity to regrow, Grade II meningiomas often require more intensive monitoring and, in some cases, additional treatment.

The increased risk associated with long-term progestogen use raises considerations for patients using Depo-Provera, as atypical tumors can lead to more complex health outcomes over time.

Grade III Meningiomas (Cancerous)

Grade III meningiomas are malignant and aggressive, though they were the least observed tumor type in the study among users of medroxyprogesterone acetate.

While no direct association was identified between progestogen exposure and the development of malignant meningiomas, the study’s findings emphasize the importance of further investigation.

The link between progestogen exposure and the more common, non-cancerous meningiomas suggests that long-term hormonal influence may still play a role in tumor progression for certain patients.

If you or a loved one suffered severe side effects after receiving the Depo-Provera birth control shot, you may be eligible to seek compensation.

Contact TruLaw using the chat on this page to receive an instant case evaluation that can determine if you qualify for the Depo-Provera brain tumor lawsuit today.

How to File a Depo-Provera Lawsuit

Filing a claim in the Depo-Provera meningioma lawsuits against Pfizer for Depo-Provera requires careful planning and gathering of critical evidence.

Plaintiffs claim that Depo-Provera’s use, particularly its prolonged exposure, has been linked to an increased risk of brain tumors, notably meningiomas.

Studies from the French National Health Data System indicate a significantly elevated risk of meningiomas associated with synthetic progestogens, particularly after prolonged exposure (≥ one year) to specific progestins, such as medroxyprogesterone acetate (the primary ingredient in Depo-Provera)​.

An experienced legal team will help assess your case, guide evidence collection, and work to secure potential compensation for damages.

Eligibility Criteria for Plaintiffs

To qualify for a Depo-Provera lawsuit, plaintiffs must meet specific eligibility criteria.

Potential plaintiffs should have experienced significant health complications attributed to the prolonged use of Depo-Provera.

According to recent research, exposure to high-dose progestogens, including medroxyprogesterone acetate, correlates with an increased risk of surgically treated meningiomas, especially among older women.

Eligibility factors in the Depo-Provera lawsuit may include:

• Prolonged Use of Depo-Provera: Documented use of Depo-Provera, especially for one year or longer.
• Meningioma Diagnosis: Diagnosis of a meningioma, ideally with records showing tumor grade and symptoms caused by the tumor.
• Treatment Records: Documentation of surgeries, radiation, or other treatments required due to the tumor.
• Impact on Life and Work: Evidence of how the tumor affected daily life, work capabilities, or income.
• Medical Records of Related Complications: Additional health records showing other neurological or cognitive complications that developed post-use.

Potential plaintiffs should consult a specialized attorney to confirm eligibility and understand the specific requirements based on individual case facts and the growing body of scientific evidence linking Depo-Provera and meningiomas.

Building a Strong Case: Evidence Collection

Collecting evidence is a fundamental part of building a compelling case against Pfizer.

Since meningioma cases related to Depo-Provera involve detailed medical histories and expert testimony, the evidence must be comprehensive and precise.

Studies have found that in cases where Depo-Provera and other synthetic progestogens were linked to meningiomas, the tumors were often located in high-risk areas, such as the skull base, and presented significant surgical challenges.

Key types of evidence include:

1. Medical Records: Provide records detailing the Depo-Provera prescription, diagnosis of meningioma, and any treatment plans, including surgeries, radiation, or medications.
2. Prescription History: Document your history of Depo-Provera usage, noting dosage, frequency, and any doctor visits specifically concerning its prescription.
3. Scientific Research Supporting Claims: Reference relevant studies, such as the recent French national case-control study, which links prolonged exposure to progestogens, including medroxyprogesterone acetate, with an elevated risk of developing intracranial meningioma.
4. Personal Impact Documentation: Include records of how the tumor affected daily life and work, such as employment records showing time off or income loss.
5. Expert Testimony: In situations where medical expertise is beneficial, expert opinions from professionals familiar with the link between Depo-Provera and meningiomas can strengthen the claim.

Assembling these elements with the support of experienced legal representation can significantly improve the strength of your lawsuit and your chances of receiving fair compensation.

If you or a loved one has been diagnosed with a meningioma after prolonged use of Depo-Provera, you may be eligible for compensation.

Contact TruLaw using the chat on this page to receive an instant case evaluation and determine whether you qualify to file a Depo-Provera lawsuit.

Damages in Depo-Provera Lawsuits

Patients who develop meningiomas linked to Depo-Provera may seek damages in a lawsuit against Pfizer for the physical, emotional, and financial impacts of their diagnosis.

These cases focus on compensating individuals for both immediate and ongoing harm.

In these claims, plaintiffs often present evidence of health complications associated with long-term synthetic hormone exposure, particularly from the active ingredient in Depo-Provera, medroxyprogesterone acetate.

A recent study demonstrated a notable risk increase of meningiomas for those with prolonged progestin exposure, which may serve as essential evidence in supporting claims for damages.

Types of Compensable Damages

If successful, plaintiffs in Depo-Provera lawsuits may be eligible for various types of compensable damages.

These are designed to address the multifaceted impact of meningioma diagnoses and treatment on their lives.

The main categories of compensable damages include:

• Medical Expenses: Covers the cost of diagnostic tests, surgeries, radiation, and other treatments required due to the meningioma.This includes both current and projected future expenses.
• Lost Wages: Compensates for income lost during treatment and recovery periods, including any time required for follow-up visits and therapies.
• Loss of Future Earnings: Provides compensation if the tumor or its treatment limits the plaintiff’s ability to work in the future.
• Pain and Suffering: Addresses the physical and emotional distress caused by the diagnosis, treatments, and potential lifelong impacts of the tumor.
• Loss of Consortium: In some cases, spouses may claim damages for the impact on their marital relationship and family life.

These damages are intended to provide comprehensive financial relief and support the plaintiff’s recovery, acknowledging the profound effects that serious diagnoses like meningiomas can have on personal and professional life.

Factors Influencing Settlement Amounts

Settlement amounts for Depo-Provera lawsuits can vary greatly and be influenced by several factors.

These factors help determine the extent of financial compensation plaintiffs may receive if the case is successful.

Key factors affecting settlement amounts include:

1. Severity of the Tumor: Higher settlements may be awarded for malignant or atypical meningiomas (Grade II or III) that require extensive treatment and pose significant health risks.Evidence from the French national study reinforces the potential for higher compensation in cases involving these more serious forms of meningioma.
2. Impact on Daily Life and Work: Cases where the meningioma has led to significant cognitive or physical limitations, affecting the plaintiff’s ability to work or perform daily activities, typically resulting in higher settlements.
3. Duration and Extent of Depo-Provera Use: Settlement amounts may also depend on the documented duration of Depo-Provera use, with long-term users facing a potentially higher risk and, therefore, more substantial claims for damages.
4. Prognosis and Ongoing Treatment Needs: Cases that involve ongoing or indefinite treatment, such as regular imaging, medication, or rehabilitative services, may yield higher compensation due to the enduring financial burden.
5. Availability of Supporting Evidence: Scientific research, such as the recent study on progestin-associated meningioma risks, may strengthen individual claims by establishing a documented link between Depo-Provera and meningioma development.

The final settlement amount in Depo-Provera cases will reflect a comprehensive evaluation of these factors, with experienced Depo-Provera lawyers working to ensure that all relevant damages are appropriately compensated.

TruLaw: Your Depo-Provera Law Firm

Depo-Provera lawsuits are being filed by individuals across the country who were diagnosed with meningioma or other severe health conditions after using the contraceptive injection.

TruLaw is currently accepting clients for the Depo-Provera lawsuit.

A few reasons to choose TruLaw for your Depo-Provera lawsuit include:

• If We Don’t Win, You Don’t Pay: The Depo-Provera lawsuit lawyers at TruLaw and our partner firms operate on a contingency fee basis, meaning we only get paid if you win.
• Expertise: We have years of experience handling pharmaceutical liability cases similar to the Depo-Provera lawsuit, which helps us anticipate what we can expect to see in your case and the regulations we will be required to meet.
• Successful Track Record: TruLaw and our partner law firms have helped our clients recover billions of dollars in compensation through verdicts and negotiated settlements.

If you or a loved one were diagnosed with any grade of meningioma or suffered from other severe health conditions after using Depo-Provera, you may be eligible to seek compensation.

Contact TruLaw using the chat on this page to receive an instant case evaluation that can determine if you qualify for the Depo-Provera lawsuit today.